Encyclopedia entry

Peptide therapy for weight loss

"Peptide therapy for weight loss" is a confusing phrase because it covers two very different things. Almost always, the searcher means a licensed GLP-1 medicine such as semaglutide or tirzepatide, which is itself a peptide and is the evidence-backed weight-loss route in the UK. Separately, some private clinics use "peptide therapy" to market research peptides around metabolism and body composition. Those are sold research use only, with no human trials for weight loss, and are a different category entirely.

The route that has the evidence

GLP-1 medications (semaglutide, tirzepatide) are licensed prescription medicines with large randomised trials behind them. They are accessed through the NHS or a regulated UK clinic or pharmacy. Whether one is appropriate for a given person is a decision for a prescriber, not something decided from a marketing page.

What "peptide therapy" research peptides are, in this context

• · Research peptides marketed around metabolism or recovery (for example AOD-9604, MOTS-c, fragment peptides) are sold under research-use-only wording.
• · There are no published human randomised trials supporting them for weight loss.
• · The research-use-only label is what allows them to be supplied; it does not authorise human treatment. PeptideClear reports this and makes no efficacy claim.

The short version

If weight loss is the goal, the licensed, evidence-backed option is a GLP-1 medication, and suitability is a prescriber decision. The research peptides marketed as "peptide therapy" sit outside that evidence base.

Related: Peptide therapy vs GLP-1 · What is peptide therapy · "Research use only" framing · NHS GLP-1 access.